Entera Bio (ENTX) Common Equity (2017 - 2026)

Entera Bio has disclosed Common Equity across 9 years of filings, most recently posting $10.7 million for Q1 2026.

• Quarterly Common Equity fell 44.85% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 44.85% YoY) and the FY2025 annual result came in at $13.1 million, up 62.14% from the prior year.
• Common Equity fell to $10.7 million in Q1 2026, from $13.1 million in the prior quarter.
• Over five years, Common Equity peaked at $19.7 million in Q1 2022 and troughed at $6.2 million in Q3 2023.
• A 5-year average of $12.1 million and a median of $10.7 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity sank 56.43% — and 2025, when it soared 136.11%.
• Tracing ENTX's Common Equity over 5 years: stood at $11.8 million in 2022, then retreated by 11.64% to $10.4 million in 2023, then declined by 22.2% to $8.1 million in 2024, then surged by 62.14% to $13.1 million in 2025, then decreased by 18.43% to $10.7 million in 2026.
• Business Quant data shows ENTX's Common Equity at $10.7 million in Q1 2026, $13.1 million in Q4 2025, and $15.2 million in Q3 2025.